CioboataRBalteanuMAOsmanA, et al.Coinfections in tuberculosis in low- and middle-income countries: Epidemiology, clinical implications, diagnostic challenges, and management strategies – a narrative review. J Clin Med2025; 14: 2154.
2.
KimCYHaJWJungI, et al.Risk of gout among patients with tuberculosis: A nationwide cohort study in South Korea. Int J Rheum Dis2025; 28: e70197.
3.
McAllisterWThompsonPAl-HabetS, et al.Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed)1983; 286: 923–925.
4.
DaoussisDKordasPVarelasG, et al.ACTH Vs steroids for the treatment of acute gout in hospitalized patients: a randomized, open label, comparative study. Rheumatol Int2022; 42: 949–958.
5.
NisarM. Crystallising the role of adrenocorticotrophic hormone in the management of acute gout: A review. Clin Exp Rheumatol2019; 37: 137–145.
6.
JanssenCAOude VoshaarMAHVonkemanHE, et al.Anakinra for the treatment of acute gout flares: A randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology2019; 58: 1344–1352.
7.
PillingerMHMandellBF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum2020; 50: S24–S30.
8.
KannuthuraiVGaffoA. Management of patients with gout and kidney disease: A review of available therapies and common missteps. Kidney3602023; 4: E1332–E1340.
9.
van ArkelCBoereeMMagis-EscurraC, et al.Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series. Med2022; 3: 603–611.
